PDX Model Market Size & Analysis Report by Type, By Tumor type, By Application, By End-user and By Region – Global Opportunities & Forecast 2021-2028
PDX Model Market Size & Analysis Report by Type (Mice Models and Rat Models), By Tumor type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models and Others), By Application (Preclinical Drug Development, Biomarker Analysis and Basic Cancer Research), By End-user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutions) and By Region
1. Executive Summary
1.1. Key Market Insights
2. Introduction
2.1. Study Objectives
2.2. Market Definition
2.2.1. Market Covered
2.2.2. Regional Coverage
2.2.3. Study Years & Currency
2.3. Market Stakeholders
2.4. Key Questions this Study will Answer
2.5. GMI Research’s Approach & Methodology
2.5.1. Research Data
2.5.2. Primary Data
2.5.3. Demand Side and Supply Side Analysis
2.5.4. Market Size Estimation
2.5.5. Research Assumptions
3. Global PDX Model Market- Overview
3.1. Introduction
3.2. Market Segmentation
3.3. Value Chain Analysis
3.4. Market Drivers
3.5. Market Restraints
3.6. Market Trends
4. Global PDX Model Market Revenue Forecast till 2028
5. Global PDX Model Market by Type Revenue Forecast till 2028
5.1. Mice Models
5.2. Rat Models
6. Global PDX Model Market by Tumor type Revenue Forecast till 2028
6.1. Gastrointestinal Tumor Models
6.2. Gynecological Tumor Models
6.3. Respiratory Tumor Models
6.4. Urological Tumor Models
6.5. Hematological Tumor Models
6.6. Others
7. Global PDX Model Market by Application Revenue Forecast till 2028
7.1. Preclinical Drug Development
7.2. Biomarker Analysis
7.3. Basic Cancer Research
8. Global PDX Model Market by End-user Revenue Forecast till 2028
8.1. Pharmaceutical & Biotechnology Companies
8.2. Contract Research Organizations (CROs)
8.3. Academic & Research Institutions Commercial
9. Global PDX Model Market by Region Forecast till 2028
9.1. North America PDX Model Market Revenue Forecast till 2028
(Option 1: As a part of the free 25% customization)
9.1.1. North America PDX Model Market by Type
9.1.1.1. Mice Models
9.1.1.2. Rat Models
9.1.2. North America PDX Model Market by Tumor type
9.1.2.1. Gastrointestinal Tumor Models
9.1.2.2. Gynecological Tumor Models
9.1.2.3. Respiratory Tumor Models
9.1.2.4. Urological Tumor Models
9.1.2.5. Hematological Tumor Models
9.1.2.6. Others
9.1.3. North America PDX Model Market by Application
9.1.3.1. Preclinical Drug Development
9.1.3.2. Biomarker Analysis
9.1.3.3. Basic Cancer Research
9.1.4. North America PDX Model Market by End-user
9.1.4.1. Pharmaceutical & Biotechnology Companies
9.1.4.2. Contract Research Organizations (CROs)
9.1.4.3. Academic & Research Institutions Commercial
9.1.5. US PDX Model Market All-Up
9.1.6. Canada PDX Model Market All-Up
9.2. Europe PDX Model Market Revenue Forecast till 2028
(Option 2: As a part of the free 25% customization)
9.2.1. Europe PDX Model Market by Type
9.2.1.1. Mice Models
9.2.1.2. Rat Models
9.2.2. Europe PDX Model Market by Tumor type
9.2.2.1. Gastrointestinal Tumor Models
9.2.2.2. Gynecological Tumor Models
9.2.2.3. Respiratory Tumor Models
9.2.2.4. Urological Tumor Models
9.2.2.5. Hematological Tumor Models
9.2.2.6. Others
9.2.3. Europe PDX Model Market by Application
9.2.3.1. Preclinical Drug Development
9.2.3.2. Biomarker Analysis
9.2.3.3. Basic Cancer Research
9.2.4. Europe PDX Model Market by End-user
9.2.4.1. Pharmaceutical & Biotechnology Companies
9.2.4.2. Contract Research Organizations (CROs)
9.2.4.3. Academic & Research Institutions Commercial
9.2.5. UK PDX Model Market All-Up
9.2.6. Germany PDX Model Market All-Up
9.2.7. France PDX Model Market All-Up
9.2.8. Spain PDX Model Market All-Up
9.2.9. Rest of Europe PDX Model Market All-Up
9.3. Asia-Pacific PDX Model Market Revenue Forecast till 2028
(Option 3: As a part of the free 25% customization)
9.3.1. Asia-Pacific PDX Model Market by Type
9.3.1.1. Mice Models
9.3.1.2. Rat Models
9.3.2. Asia-Pacific PDX Model Market by Tumor type
9.3.2.1. Gastrointestinal Tumor Models
9.3.2.2. Gynecological Tumor Models
9.3.2.3. Respiratory Tumor Models
9.3.2.4. Urological Tumor Models
9.3.2.5. Hematological Tumor Models
9.3.2.6. Others
9.3.3. Asia-Pacific PDX Model Market by Application
9.3.3.1. Preclinical Drug Development
9.3.3.2. Biomarker Analysis
9.3.3.3. Basic Cancer Research
9.3.4. Asia-Pacific PDX Model Market by End-user
9.3.4.1. Pharmaceutical & Biotechnology Companies
9.3.4.2. Contract Research Organizations (CROs)
9.3.4.3. Academic & Research Institutions Commercial
9.3.5. China PDX Model Market All-Up
9.3.6. India PDX Model Market All-Up
9.3.7. Japan PDX Model Market All-Up
9.3.8. Rest of APAC PDX Model Market All-Up
9.4. RoW PDX Model Market Revenue Forecast till 2028
(Option 4: As a part of the free 25% customization)
9.4.1. RoW PDX Model Market by Type
9.4.1.1. Mice Models
9.4.1.2. Rat Models
9.4.2. RoW PDX Model Market by Tumor type
9.4.2.1. Gastrointestinal Tumor Models
9.4.2.2. Gynecological Tumor Models
9.4.2.3. Respiratory Tumor Models
9.4.2.4. Urological Tumor Models
9.4.2.5. Hematological Tumor Models
9.4.2.6. Others
9.4.3. RoW PDX Model Market by Application
9.4.3.1. Preclinical Drug Development
9.4.3.2. Biomarker Analysis
9.4.3.3. Basic Cancer Research
9.4.4. RoW PDX Model Market by End-user
9.4.4.1. Pharmaceutical & Biotechnology Companies
9.4.4.2. Contract Research Organizations (CROs)
9.4.4.3. Academic & Research Institutions Commercial
9.4.5. Brazil PDX Model Market All-Up
9.4.6. South Africa PDX Model Market All-Up
9.4.7. Saudi Arabia PDX Model Market All-Up
9.4.8. UAE PDX Model Market All-Up
9.4.9. Rest of world (remaining countries of the LAMEA region) PDX Model Market All-Up
10. Competitive Landscape Analysis
10.1. Porter’s Five Forces Analysis
10.2. Industry – Competitive Landscape
10.3. Market Presence (Intensity Mapping)
10.4. Key Strategic Market Developments
11. Company Profiles (Option 5: Free 25% Customization - Profiles of 5 Additional Companies of your Choice)
11.1. JSR Corporation.
11.1.1. Company Overview
11.1.2. Key Executives
11.1.3. Footprint & Employee Strength
11.1.4. Product Offerings
11.1.5. Financials
11.1.6. Key Company Developments
11.2. WuXi AppTec
11.2.1. Company Overview
11.2.2. Key Executives
11.2.3. Footprint & Employee Strength
11.2.4. Product Offerings
11.2.5. Financials
11.2.6. Key Company Developments
11.3. THE JACKSON LABORATORY
11.3.1. Company Overview
11.3.2. Key Executives
11.3.3. Footprint & Employee Strength
11.3.4. Product Offerings
11.3.5. Financials
11.3.6. Key Company Developments
11.4. Charles River Laboratories.
11.4.1. Company Overview
11.4.2. Key Executives
11.4.3. Footprint & Employee Strength
11.4.4. Product Offerings
11.4.5. Financials
11.4.6. Key Company Developments
11.5. Oncodesign
11.5.1. Company Overview
11.5.2. Key Executives
11.5.3. Footprint & Employee Strength
11.5.4. Product Offerings
11.5.5. Financials
11.5.6. Key Company Developments
11.6. Envigo
11.6.1. Company Overview
11.6.2. Key Executives
11.6.3. Footprint & Employee Strength
11.6.4. Product Offerings
11.6.5. Financials
11.6.6. Key Company Developments
11.7. Pharmatest Services
11.7.1. Company Overview
11.7.2. Key Executives
11.7.3. Footprint & Employee Strength
11.7.4. Product Offerings
11.7.5. Financials
11.7.6. Key Company Developments
11.8. Hera Biolabs.
11.8.1. Company Overview
11.8.2. Key Executives
11.8.3. Footprint & Employee Strength
11.8.4. Product Offerings
11.8.5. Financials
11.8.6. Key Company Developments
11.9. EPO Berlin-Buch GmbH
11.9.1. Company Overview
11.9.2. Key Executives
11.9.3. Footprint & Employee Strength
11.9.4. Product Offerings
11.9.5. Financials
11.9.6. Key Company Developments
11.10. Xentech
11.10.1. Company Overview
11.10.2. Key Executives
11.10.3. Footprint & Employee Strength
11.10.4. Product Offerings
11.10.5. Financials
11.10.6. Key Company Developments
12. About GMI Research
*Details on Financials might not be available in case of unlisted/private companies.
*The list of companies is based on preliminary research in this sample report, the companies in the final report may change based on research findings.
- Published Date: Jul - 2021
- Report Format: Excel/PPT
- Report Code: UP2115-001001
Licensing Options
Single-User License:
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
PDX Model Market Size & Analysis Report by Type, By Tumor type, By Application, By End-user and By Region – Global Opportunities & Forecast 2021-2028
$ 4,499.00 – $ 6,649.00
Why GMI Research
